<DOC>
	<DOCNO>NCT02912455</DOCNO>
	<brief_summary>This prospective , randomized clinical trial patient recurrent type 2 diabetes post-gastric bypass surgery compare 6 month course canagliflozin monotherapy vs. placebo clinical outcome type 2 diabetes .</brief_summary>
	<brief_title>CARAT : Canagliflozin v . Placebo Post Bariatric Patients With Persistent Type 2 Diabetes</brief_title>
	<detailed_description>Following consent screen visit ass eligibility clinical status ( i.e . historical , physical biochemical parameter include glycemic control pregnancy test female ) , baseline visit diabetes educator take place provide standard diabetes education , nutrition exercise prescription . Nutritional assessment vitamin/mineral deficiency perform per clinical care guideline screen visit . Subjects asked take nutritional supplement ( i.e . vitamin mineral ) per current clinical guideline post-bariatric patient . Stable dose supplement establish least 2 week prior randomization . Thirty-six subject recurrent diabetes naïve hypoglycemic agent HbA1c great equal 6.5 % le 10 % randomly assign six month course ) canagliflozin 100mg 2 week titrate 300 mg daily ( N = 24 ) vs. placebo ( n= 12 ) randomization . Patients use metformin ask wash 8 week prior screen visit . At randomization , biochemical assessment glycemic parameter ( fast glucose , HbA1c ) , lipid panel , complete metabolic panel , uric acid , leptin , total HMW adiponectin , C-reactive protein urine albumin/creatinine ratio perform . Dual-energy x-ray absorptiometry ( DXA ) scan perform body fat composition . Following randomization , subject clinically evaluate three office visit 6 week , 3 6 month PI and/or research staff . The primary outcome measure 6 month post-randomization include HbA1c follow change HbA1c randomization . Secondary measure include fast glucose , BMI , change body weight , blood pressure , lipid profile . Symptomatic hypoglycemia ( blood glucose &lt; 70 ) drug relate side effect ( i.e . mycotic genital infection , urinary tract infection ) monitor adverse event reporting . Metabolic test subject randomization 6 month include DXA scan body fat composition blood leptin adiponectin level . Rescue glucose lower therapy provide control group blood glucose &gt; 250 mg/dl . If chronic uncontrolled hyperglycemia ( HbA1c &gt; 10 % ) occur basal bolus insulin implement .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Post RouxnY gastric bypass ( RYGB ) surgery sleeve gastrectomy ( SG ) patient underwent surgery &gt; 1 &lt; 10 year ago Cleveland surround area Age 2065 year age Type II Diabetes Mellitus ( D2M ) diagnosis ( history , medication usage , biochemical criterion ) prior surgery ; surgery , define single HbA1c great equal 6.5 % consent screening . Metformin patient must HbA1c great equal 6.5 % less equal 10 % randomization ; diet control patient ( i.e . T2D medication ) , HbA1c must great equal 6.5 % randomization . Patient reporting improvement T2D status objective improvement T2D status time postsurgery . estimate glomerular filtration rate ( eGFR ) ≥ 60mL/min prior randomization Has ability willingness provide inform consent . Is able understand option comply requirement program Female subject agree serum pregnancy test screening . A negative serum pregnancy test result require prior randomization . Female patient must agree use reliable method contraception 6 month duration intervention Patients take Metformin eligible must agree washout 8 week prior baseline visit . Type 1 diabetes indicate history diabetic ketoacidosis lack remission response bariatric surgery Other post bariatric procedure ( band , duodenal switch , biliopancreatic diversion ) Use insulin analog , incretin analog antidiabetic agent postsurgery . End organ diabetic complication ( renal failure , cardiomyopathy , severe neuropathy/foot ulcer ) Documented severe unstable depression/anxiety eat disorder would enable patient adhere antidiabetic treatment Clinical contraindication use canagliflozin , i.e. , history bladder cancer , ChildPugh class C</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Post-Bariatric Surgery</keyword>
	<keyword>hemoglobin A1c protein , human</keyword>
</DOC>